ChromaDex launches Niagen
Niagen joins the portfolio of B-vitamin ingredients that are used in multi-vitamins, nutraceuticals, weight-loss, energy drinks, sports nutrition, meal replacements, and infant formula, food and beverage products. ChromaDex
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.
Indicated for patients with exocrine pancreatic insufficiency (EPI), 36,000 lipase-unit dose of the pancreatic enzyme replacement therapy was approved by the FDA. University of Pittsburgh gastroenterology, hepatology and